Widespread racial disparities in use of BRCA 1/2 counseling

Article

African-American women with a family history of breast or ovarian cancer are only about one fifth as likely as white counterparts to receive genetic counseling for BRCA 1/2 testing (OR 0.22; 95% CI; 0.12–0.40), according to a recent case-control study from Philadelphia.

African-American women with a family history of breast or ovarian cancer are only about one fifth as likely as white counterparts to receive genetic counseling for BRCA 1/2 testing (OR 0.22; 95% CI; 0.12–0.40), according to a recent case-control study from Philadelphia.

The study included 408 women with a family history of either disease, of whom 217 received genetic counseling and 191 did not. Even after adjusting for the probability of a BRCA 1/2 mutation, socioeconomic characteristics, breast and ovarian cancer risk perception and worry, attitudes about the risk and benefits of BRCA 1/2 testing, and primary-care physician discussion of BRCA 1/2 testing, researchers calculated an odds ratio of 0.28 (95% CI; 0.09–0.89) for African-American women receiving counseling.

Armstrong K, Micco E, Carney A, et al. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293:1729-1736.

Recent Videos
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
© 2024 MJH Life Sciences

All rights reserved.